Thermogenesis
This article was originally published in The Gray Sheet
Executive Summary
Gains FDA marketing clearance for the automated CryoSeal system for production of cryoprecipitated AHF anti-hemophilic factor, production of which represents a $100 mil. market, according to the company. The firm touts the system's ability to produce AHF on-site within an hour, versus two or three days with traditional manual production. Clinical trials in support of additional indications for producing autologous fibrin glue and autologous platelet derived growth factors will begin in late 1999, Thermogenesis says
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.